Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

March 9, 2018

Study Completion Date

March 9, 2018

Conditions
Stress Disorders, Post-TraumaticBulimia Nervosa
Interventions
DRUG

Prazosin

A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.

DRUG

Placebo

Prazosin-matched placebo pill

DRUG

Prazosin

A starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.

DRUG

Placebo

Prazosin-matched placebo pill

Trial Locations (1)

17033

Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey

All Listed Sponsors
lead

Milton S. Hershey Medical Center

OTHER

NCT02382848 - Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD | Biotech Hunter | Biotech Hunter